IPO of Gracell Biotechnologies, Inc.

Gracell Biotechnologies, Inc. has placed 11 000 000 of American depositary shares (ADSs) in an IPO priced $19 per share, which is $1 above the upper limit of the previously announced range ($16-18). Besides, Gracell has granted the underwriters a 30-day option to purchase up to 1 650 000 of ADSs at the public offering price. 
The trading debut will take place on the Nasdaq Global Select Market on January 8, 2021 under the ticker symbol “GRCL”.